n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis. by Frigerio, F et al.
n-3 Docosapentaenoic acid-derived protectin
D1 promotes resolution of neuroinflammation
and arrests epileptogenesis
Federica Frigerio,1 Giulia Pasqualini,1 Ilaria Craparotta,2 Sergio Marchini,2
Erwin A. van Vliet,3 Patrick Foerch,4 Catherine Vandenplas,4 Karin Leclercq,4
Eleonora Aronica,3,5 Luca Porcu,2 Kimberly Pistorius,6 Romain A. Colas,6 Trond V. Hansen,7
Mauro Perretti,6,8 Rafal M. Kaminski,4,* Jesmond Dalli6,8,* and Annamaria Vezzani1,*
*These authors contributed equally to this work.
Epilepsy therapy is based on drugs that treat the symptoms rather than the underlying mechanisms of the disease (epileptogenesis).
There are no treatments for preventing seizures or improving disease prognosis, including neurological comorbidities. The search of
pathogenic mechanisms of epileptogenesis highlighted that neuroinﬂammatory cytokines [i.e. interleukin-1b (IL-1b), tumour necrosis
factor-a (Tnf-a)] are induced in human and experimental epilepsies, and contribute to seizure generation in animal models. A major role
in controlling the inﬂammatory response is played by specialized pro-resolving lipid mediators acting on speciﬁc G-protein coupled
receptors. Of note, the role that these pathways have in epileptogenic tissue remains largely unexplored. Using a murine model of
epilepsy, we show that specialized pro-resolving mechanisms are activated by status epilepticus before the onset of spontaneous seizures,
but with a marked delay as compared to the neuroinﬂammatory response. This was assessed by measuring the time course of mRNA
levels of 5-lipoxygenase (Alox5) and 15-lipoxygenase (Alox15), the key biosynthetic enzymes of pro-resolving lipid mediators, versus
Il1b and Tnfa transcripts and proteins. In the same hippocampal tissue, we found a similar delayed expression of two main pro-
resolving receptors, the lipoxin A4 receptor/formyl peptide receptor 2 and the chemerin receptor. These receptors were also induced in
the human hippocampus after status epilepticus and in patients with temporal lobe epilepsy. This evidence supports the hypothesis that
the neuroinﬂammatory response is sustained by a failure to engage pro-resolving mechanisms during epileptogenesis. Lipidomic LC-MS/
MS analysis showed that lipid mediator levels apt to resolve the neuroinﬂammatory response were also signiﬁcantly altered in the
hippocampus during epileptogenesis with a shift in the biosynthesis of several pro-resolving mediator families including the n-3
docosapentaenoic acid (DPA)-derived protectin D1. Of note, intracerebroventricular injection of this mediator during epileptogenesis
in mice dose-dependently reduced the hippocampal expression of both Il1b and Tnfa mRNAs. This effect was associated with marked
improvement in mouse weight recovery and rescue of cognitive deﬁcit in the novel object recognition test. Notably, the frequency of
spontaneous seizures was drastically reduced by 2-fold on average and the average seizure duration was shortened by 40% after
treatment discontinuation. As a result, the total time spent in seizures was reduced by 3-fold in mice treated with n-3 DPA-derived
protectin D1. Taken together, the present ﬁndings demonstrate that epilepsy is characterized by an inadequate engagement of resolution
pathways. Boosting endogenous resolution responses signiﬁcantly improved disease outcomes, providing novel treatment avenues.
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Introduction
Epilepsy is a brain disease that affects around 65 million
people worldwide (Devinski et al., 2018). Epileptic seizures,
the hallmarks of epilepsy, reduce the quality of life, increase
the risk of death, and impose socio-economic burdens to
affected people and society. Despite the availability of a
signiﬁcant number of anti-seizure drugs, 30% of newly
diagnosed epilepsy patients are resistant to therapies (Kwan
et al., 2011; Loscher et al., 2013). Moreover, there are no
drugs able to prevent the onset or progression of epilepsy in
patients exposed to epileptogenic injuries, such as status
epilepticus, trauma, stroke or CNS infections. Thus, next
generation therapies should target the mechanisms of epi-
leptogenesis to either prevent the disease or improve its
outcomes (Loscher et al., 2013).
Neuroinﬂammation is a mechanism of epileptogenesis
commonly induced in seizure-susceptible brain areas by dif-
fering brain injuries (Aronica et al., 2017; Klein et al.,
2018). It persists in chronic epilepsy in both experimental
animals and patients (Aronica and Crino, 2011; Butler
et al., 2016; Klein et al., 2018). Neuroinﬂammation is
characterized by increased cytokines, such as interleukin-
1b (IL-1b), tumour necrosis factor- (TNF-), high mobility
group box 1 (HMGB1), their cognate receptors and down-
stream effector molecules in glia, neurons and blood–brain
barrier cellular components (Ravizza et al., 2006, 2008,
2011; Boer et al., 2008; Vezzani et al., 2013). These in-
ﬂammatory molecules signiﬁcantly contribute to the gener-
ation and recurrence of spontaneous seizures (Vezzani
et al., 2011a, b; Terrone et al., 2017) and to neurological
comorbidities (Mazarati et al., 2017) in animal models.
There is evidence that the neuroinﬂammatory milieu per-
sists in epilepsy because is not efﬁciently controlled by en-
dogenous anti-inﬂammatory mechanisms (Ravizza et al.,
2006; Aronica et al., 2007; Pernhorst et al., 2013; Sun
et al., 2016), thereby contributing to dysfunction of brain
cells and neuronal network hyperexcitability (Vezzani et al.,
2011b; Vezzani and Viviani, 2015). In support, pharmaco-
logical or genetic interventions for increasing the endogen-
ous anti-inﬂammatory IL-1 receptor antagonist (IL-1Ra,
encoded by IL1RN) drastically reduced the frequency of
seizures in experimental models (De Simoni et al., 2000;
Vezzani et al., 2000, 2002; Librizzi et al., 2012; Bertani
et al., 2017; Walker et al., 2017) and in humans
(Jyonouchi, 2016; Kenney-Jung et al., 2016; DeSena
et al., 2018), afforded neuroprotection (Noe´ et al., 2013)
and rescued neurological deﬁcits (Mazarati et al., 2017).
Specialized pro-resolving mediators (e.g. lipoxins, resol-
vins, protectins and maresins) are key molecules that medi-
ate the active resolution of inﬂammation in peripheral
tissues and in CNS (Serhan et al., 2008). The biosynthesis
of these mediators occurs through the stereoselective con-
version of essential fatty acids, including eicosapentaenoic
acid (EPA), docosahexaenoic acid (DHA) and n-3 docosa-
pentaenoic acid (DPA), by lipoxygenase (LOX) and
cyclooxygenase enzymes (Serhan et al., 2017). The biolo-
gical actions of these molecules are mediated by cognate
G-protein coupled receptors, including the lipoxin A4 recep-
tor/formyl peptide receptor 2 (ALX/FPR2) and the chemerin
receptor (ChemR23/ERV1), to drive active resolution of in-
ﬂammation. This is attained by reducing the expression of
proinﬂammatory cytokines and chemokines, orchestrating
the trafﬁcking of innate and adaptive immune cells to the
inﬂamed tissue, restoring the blood–brain barrier integrity
(Cristante et al., 2013) and increasing anti-inﬂammatory
molecules (Serhan et al., 2008).
Pro-resolving mediators exert beneﬁcial actions in a range
of preclinical models of peripheral organ dysfunction linked
to inﬂammatory conditions (Romano et al., 2015; Serhan
et al., 2017). In the CNS, neuroprotective actions of lipox-
ins and their synthetic analogues, or neuroprotectin D1
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(NPD1) (Zhao et al., 2011) have been reported in models
of Alzheimer’s disease, ischaemia-reperfusion injury or neu-
rotrauma where these molecules also alleviate the neuro-
logical symptoms (Marcheselli et al., 2003; Wu et al.,
2011; Zhao et al., 2011; Luo et al., 2013; Hawkins
et al., 2014). In models of neuropathic pain lipoxins
(Martini et al., 2016), maresin 1 (Serhan et al., 2012),
resolvins (Xu et al., 2010) and NPD1 (Xu et al., 2013)
showed analgesic properties (Romano et al., 2015; Keppel
Hesselink, 2017).
The ALX/FPR2 receptor and 15-LOX (ALOX15) are ex-
pressed in the hippocampus of patients with Alzheimer’s
disease suggesting that resolution mechanisms might be
active in human CNS diseases with a pathogenic neuroin-
ﬂammatory component. Of note, reduced levels of lipoxin
(LX)A4 in the same specimens suggest a potential alteration
of this pathway (Wang et al., 2015).
Recent studies demonstrate that DHA and the DHA-
derived NPD1 reduced neuronal hyperexcitability evoked
in vivo by electrical hippocampal kindling stimulation
(Musto et al., 2011) or injection of a chemoconvulsant in
mice (Musto et al., 2015). Moreover, n-3 polyunsaturated
fatty acids (such as EPA, DHA) decrease evoked hippocam-
pal neuronal excitability in slice preparations (Xiao and Li,
1999; Taha et al., 2013b) and there is some evidence that
they may have anticonvulsive effects in humans and animal
models (Taha et al., 2010, 2013a). However, the mechan-
isms elicited by these n-3 polyunsaturated fatty acids as
well as the role of pro-resolving pathways in epilepsy
remain to be elucidated.
In this study, we provide novel evidence of the temporal
regulation of specialized pro-resolving mediator expression
in the hippocampus during epileptogenesis, and compared
them with the kinetics of the neuroinﬂammatory response
in a mouse model of acquired chronic epilepsy (Iori et al.,
2017). We also show that lipid mediator levels apt to re-
solve the neuroinﬂammatory response are signiﬁcantly
altered during epileptogenesis, and describe the expression
of pro-resolving receptors in mouse and human epilepto-
genic hippocampi versus control brain tissue. Finally, we
determined the ability of a speciﬁc specialized pro-resolving
mediator, n-3 DPA-derived protectin D1 (PD1n-3 DPA), in
controlling the neuroinﬂammatory response during epilep-
togenesis. This intervention reduced neuroinﬂammation,
improved the post-injury animal’s weight recovery, rescued
their cognitive deﬁcit and resulted in a signiﬁcant decrease
in both frequency and duration of epileptic seizures.
Materials and methods
In accordance with the ARRIVE guidelines, procedures involving
animals and their care were conducted in conformity with the
institutional guidelines that are in compliance with national (D.L.
n.26, G.U. March 4, 2014) and international guidelines and laws
(EEC Council Directive 86/609, OJ L 358, 1, December 12,
1987, Guide for the Care and Use of Laboratory Animals, U.S.
National Research Council, 1996), and were reviewed and
approved by the intramural ethical committee.
Experimental animals
Adult male C57/BL6N mice (30g; Charles River) were used in all the
experiments, except for one experiment where adult male NMRI
mice (28–32g; Charles River) were used (Supplementary material).
C57/BL6N mice were housed at constant temperature (23 1C)
and relative humidity (60 5%) with a ﬁxed 12-h light-dark cycle
and free access to food and water. Mice were housed four per cage
until surgery, and then kept one per cage in an enriched environment
with nesting materials (Hutchinson et al., 2005).
Mouse model of epilepsy
Mice were implanted under 1.5% isoﬂurane anaesthesia with a
23-gauge cannula unilaterally positioned on top of the dura
mater for the intra-amygdala injection of kainic acid [from
bregma, mm: nose bar 0; anteroposterior (AP) 1.0, lateral
(L) 2.8]. A bipolar Teﬂon-insulated stainless-steel depth elec-
trode (60 mm outer diameter) was implanted in the dorsal
hippocampus ipsilateral to the injected amygdala (from
bregma, mm: nose bar 0; AP 1.8, L 1.5, 2.0 below
dura mater). Additionally, a cortical surface electrode was im-
planted onto the somatosensory cortex in the contralateral
hemisphere. One additional guide cannula was positioned on
top of the dura mater (from bregma, mm: nose bar 0; AP 0,
L 0.9) ipsilateral to the injected amygdala for intracerebro-
ventricular injections (Franklin and Paxinos, 2008). Finally,
two screw electrodes were positioned over the nasal sinus
and the cerebellum, and used as ground and reference elec-
trodes, respectively. Electrodes were connected to a multipin
socket and secured to the skull by acrylic dental cement (Iori
et al., 2017).
One week after surgery, mice were connected to the EEG
setup the day before beginning the experiment in order to
record an EEG baseline for at least 24 h. Kainic acid (0.3 mg
in 0.2 ml; Sigma-Aldrich, #K0250) was dissolved in 0.1M
phosphate-buffered saline (PBS, pH 7.4) and injected into the
right basolateral amygdala in freely moving mice using a
needle protruding of 4.1mm below the implanted cannula in
order to evoke status epilepticus (Iori et al., 2017).
Detection and quantification of status
epilepticus and spontaneous seizures
Status epilepticus was deﬁned by the appearance of continuous
spike activity with a frequency 41 Hz intermixed with high
amplitude and frequency discharges lasting for at least 5 s,
with a frequency of 48 Hz. Spikes were deﬁned as sharp
waves with amplitude at least 2.5-fold higher than the stand-
ard deviation of baseline signal and duration 5100ms, or as a
spike-and-wave with duration 5200ms (Pitkanen et al.,
2005). Status epilepticus developed after 10min from
kainic acid injection, as previously described (Iori et al.,
2017). After 40min from status epilepticus onset, mice were
injected with diazepam (10mg/kg, intraperitoneally) to im-
prove their survival, although EEG status epilepticus was
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not interrupted. After status epilepticus induction mice were
recorded continuously (24/7) until the onset of spontaneous
seizures was detected in each mouse (Fig. 6C) and for 16
days thereafter using the Twin EEG Recording System con-
nected with a Comet AS-40 32/8 Ampliﬁer (sampling rate
400Hz, high-pass ﬁlter 0.3Hz, low-pass ﬁlter 70Hz, sensitiv-
ity 2000mV/cm; Grass-Telefactor). Digitized EEG data were
processed using the Twin record and review software. Status
epilepticus duration and spiking activity were quantiﬁed using
Clampﬁt 9.0 program (Axon Instruments). The end of status
epilepticus was deﬁned by the occurrence of interspike inter-
vals longer than 1 s. Spontaneous motor seizures developed
5.4  0.5 days after status epilepticus (Fig. 6C) as described
previously (Jimenez-Mateos et al., 2012; Iori et al., 2017). We
calculated the total number and total duration of seizures
during a 16-day recording period (24/7) starting after the
onset of the ﬁrst spontaneous seizure in each mouse to esti-
mate the frequency of seizures and their average duration.
Although we did not record mice for a longer time, we
showed previously in this model that all mice exposed to
status epilepticus lasting for about 7 h develop spontaneous
seizures that recur for more than 2 months, and seizure fre-
quency may increase from 1.5 months onwards in a propor-
tion of mice (Iori et al., 2017).
Lipid mediator profiling
Mice were deeply anaesthetized with intraperitoneal injections
of ketamine (75mg/kg) and medetomidine (0.5mg/kg), then
perfused via ascending aorta with 50mM ice-cold PBS (pH
7.4) for 1min to remove blood, and decapitated at 72 h
post-status epilepticus. The hippocampus ipsilateral to the sti-
mulated amygdala was rapidly dissected out at 4C, immedi-
ately frozen in liquid nitrogen and stored at 80C. To have
enough tissue for the analysis, we pooled two hippocampi ip-
silateral to the stimulated amygdala from two different mice
(n = 16 mice; eight samples). Sham mice (n = 8) were injected
with vehicle instead of kainic acid; for each mouse the hippo-
campi from both hemispheres were pooled together.
Tissues were placed in 1ml of ice-cold methanol containing
500 pg each of d5-lipoxin A4 (LXA4), d5-resolvin D2 (RvD2),
d4-prostaglandin E2 (PGE2), d4-leukotriene B4 (LTB4) and d8-
5S-hydroexeicosatetraneoic acid (diHETE). The tissues were
then gently homogenized using a glass dounce. These were
then kept at 20C for 45min, to allow protein precipitation,
then centrifuged at 1500 g for 10min, 4C. All samples for
LC-MS/MS-based proﬁling were extracted using solid-phase
extraction columns (Dalli et al., 2013; Rathod et al., 2017).
Brieﬂy, supernatants were subjected to solid phase extraction,
methyl formate fraction collected, brought to dryness and sus-
pended in phase (methanol/water, 1:4, vol/vol) for injection on
a Shimadzu LC-20AD HPLC and a Shimadzu SIL-20AC auto-
injector, paired with a QTRAP 6500 plus (Sciex). An Agilent
Poroshell 120 EC-C18 column (100mm  4.6mm  2.7 mm)
was kept at 50C and mediators eluted using a mobile phase
consisting of methanol-water-acetic acid of 20:80:0.01 (vol/vol/
vol) that was ramped to 50:50:0.01 (vol/vol/vol) over 0.5min
and then to 80:20:0.01 (vol/vol/vol) from 2min to 11min,
maintained till 14.5min and then rapidly ramped to
98:2:0.01 (vol/vol/vol) for the next 0.1min. This was subse-
quently maintained at 98:2:0.01 (vol/vol/vol) for 5.4min, and
the ﬂow rate was maintained at 0.5ml/min. The QTRAP
6500 plus was operated using a multiple reaction monitoring
method (Dalli et al., 2013; Rathod et al., 2017). Each lipid
mediator was identiﬁed using established criteria including
matching retention time to synthetic materials and authentic
material and at least six diagnostic ions (Dalli et al., 2013;
Rathod et al., 2017). Calibration curves were obtained for
each mediator using synthetic and authentic standard mixtures
at 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 200pg that
gave linear calibration curves with a r2-values of 0.98–0.99.
Pharmacological treatment with
PD1n-3 DPA-ME
PD1n-3 DPA-ME, the methylester (ME) pro-drug form of
PD1n-3 DPA, which is rapidly converted by cellular esterases
to the free acid form, was prepared as previously described
(Aursnes et al., 2014). This was aliquoted in ethanol and
stored at 80C in the dark until use. Immediately prior to
administration in mice, ethanol was evaporated using a gentle
stream of nitrogen. Then, the mediator was suspended in
50mM PBS (pH 7.4), placed in a water bath sonicator for
510 s and vortexed for no more than 30 s.
Mice were exposed to status epilepticus, then they were as-
signed randomly to treatment or vehicle (50mM PBS) groups.
PD1n-3 DPA-ME (20 or 200ng/ml in 50mM PBS, pH 7.4) or ve-
hicle was injected intracerebroventricularly (1ml/site) twice daily
for four consecutive days starting 1h after status epilepticus onset.
This schedule was designed to encompass the epileptogenesis
phase preceding disease onset, then the treatment was stopped.
Supplementary methods
The Supplementary material provides further details for: real-
time quantitative polymerase chain reaction analysis (RT-
qPCR); intraperitoneal pilocarpine injection in mice; novel
object recognition test; immunohistochemistry and double-
immunostaining; human subjects; ALXR/FPR2 and ChemR23/
ERV1 immunohistochemistry in human tissue; and histological
analysis and quantiﬁcation of neuronal cell loss, neurogenesis
and glia activation.
Statistical analysis
In each animal experiment no ad interim analysis was done.
Sample size was a priori determined based on previous experi-
ence with the animal model. All efforts were made to minimize
the number of animals used and their suffering according to the
principles of the three Rs (Replacement, Reduction and
Reﬁnement; https://www.nc3rs.org.uk/the-3rs). Endpoints (out-
come measures) and statistical tests were prospectively selected.
A simple random allocation using a website randomization pro-
gram (www.randomization.com) was applied to assign a subject
to a particular experimental group. Data acquisition and ana-
lysis were done blindly.
Statistical analysis was performed by GraphPad Prism 6
(GraphPad Software, USA) for Windows using absolute
values. Data are presented as box-and-whisker plots depicting
median, interquartile interval, minimum and maximum
(n = number of individual samples). Mann Whitney U-test for
two independent groups and Kruskal-Wallis test with Dunn’s
post hoc correction for more than two independent groups
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were used for statistical analysis of data. The temporal distri-
bution of spikes during status epilepticus was analysed by two-
way ANOVA followed by Bonferroni’s multiple comparisons
test. Based on normality test’s results, one-way ANOVA with
Tukey’s post hoc test and t-test were used for behavioural
data. One tailed t-test was used for analysis of the effect of
treatment with PD1n-3DPA-ME on spontaneous seizures.
Friedman’s two-way non-parametric ANOVA was used to
detect the treatment effect on number of seizures and duration
and their interaction with days. Differences were considered
signiﬁcant with a P50.05.
Data availability
The data that support the ﬁndings of this study are available
from the corresponding author, upon reasonable request.
Results
Distinct temporal regulation of
pro-resolving mediators versus
neuroinflammatory mediators
during epileptogenesis
As an index of neuroinﬂammation, we measured Il1b and
Tnfa mRNA levels by RT-qPCR in the mouse hippocampus
from 2h until 7 days post-status epilepticus to encompass
the epileptogenesis phase preceding the onset of spontaneous
seizures. Figure 1A and C shows a signiﬁcant increase in
Il1b and Tnfa transcripts between 2h and 72h (n = 7–10)
Figure 1 Temporal regulation of pro-resolving pathways in mouse hippocampus during epileptogenesis. Messenger RNA (A and
C) and protein expression (B and D) of IL1B (IL-1b) and TNFA (TNF-) and mRNA expression of Alox5 (5-LOX, B) and Alox15 (15-LOX, F) from
2 h until 7 days post-status epilepticus. Reference genes were Mfsd5, Brap, Bcl2l13. Data are presented on a log10 scale as box-and-whisker plots
depicting median, interquartile interval, minimum and maximum (n = 7–10). *P5 0.05, **P5 0.01 versus sham by Kruskal-Wallis test with Dunn’s
post hoc correction. In the high magnification panels in B and D, we identified the cell types expressing IL-1b and TNF- (green) by double-
immunostaining using specific astrocytic (GFAP, red) and microglial (CD11b, red) cell markers. Co-localization signal is depicted in yellow. Scale
bar = 50mm.
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compared to sham mice (n = 7), declining to basal values
thereafter. The increase in cytokines was conﬁrmed by
immunohistochemistry (Fig. 1B and D) showing that both
IL-1b and Tnf- staining was induced in activated GFAP-
positive astrocytes 72h post-status epilepticus (n = 8). No
CD3-positive lymphocytes were observed in brain tissue
(not shown). Cytokines were undetectable in control hippo-
campi (sham, n = 8) or in CD11b-positive microglia 72 h
after status epilepticus in mice (Fig. 1B and D, colour micro-
graphs), which is in line with previous ﬁndings (De Simoni
et al., 2000; Maroso et al., 2011).
To assess the potential impact of specialized pro-resolving
mediators in these settings we determined the mRNA expres-
sion of Alox5 (5-LOX) and Alox15 (15-LOX), two key en-
zymes in the biosynthesis of pro-resolving mediators. In
tissues from epileptogenic mice we found a signiﬁcant upre-
gulation of both enzymes at the 72h interval (Fig. 1E and F;
n = 7–10 mice). To establish whether these results were also
reproduced in a distinct model of epilepsy, we administered
pilocarpine to mice and assessed the expression of both in-
ﬂammatory and pro-resolving molecules in the hippocampus.
We found a signiﬁcant upregulation of both inﬂammatory
and pro-resolving mediators tested at the 72h interval
(Supplementary Fig. 1). These results support the hypothesis
that neuroinﬂammation in epileptogenesis may arise from a
failure to engage pro-resolving mechanisms.
We also investigated the expression of two main pro-resol-
ving receptors ALX/FPR2 and ChemR23/ERV1 in mouse
(Supplementary Fig. 2A–D) and human (Supplementary Fig.
2E and F) epileptogenic tissues. In the mouse hippocampus
the mRNA level of either receptor was increased above control
value at 72h (n = 7) but not at 2h and 7 days after status
epilepticus (n = 7–10). ALXR/FPR2 induction was measured at
24h post-status epilepticus therefore anticipating ChemR23/
ERV1 increase (Supplementary Fig. 2A and C). Both ALX/
FPR2 and ChemR23/ERV1 immunostaining was increased in
GFAP-positive astrocytes but not in CD11b-positive microglia
72h post-status epilepticus (n = 8) (Supplementary Fig. 2B and
D, colour micrographs). ALX/FPR2 and IL-1b proteins were
co-localized in astrocytes (micrograph in Supplementary Fig.
2B) suggesting that the resolution signalling process is operative
within the cells that generate neuroinﬂammatory molecules.
Similar to status epilepticus-exposed mice, ALX/FPR2 and
ChemR23/ERV1 were predominantly induced in astrocytes in
hippocampal specimens from patients who died 1–49 days
after status epilepticus and in chronic epilepsy patients (n = 7;
Supplementary Fig. 2E and F) as compared to autoptic control
tissue (n = 6).
Epileptogenesis alters mouse
hippocampal specialized
pro-resolving mediator profiles
Given that we found an alteration in resolution mechanisms
and an upregulation in the expression of specialized pro-
resolving mediator biosynthetic enzymes during murine
epileptogenesis, we next assessed whether specialized pro-
resolving mediator biosynthesis was also altered. Using LC-
MS/MS-based lipid mediator proﬁling we identiﬁed medi-
ators from all four major bioactive metabolomes that were
identiﬁed in accordance to established criteria, including re-
tention times and MS/MS spectra (Dalli et al., 2018) (Fig. 2A
and B). These included the DHA-derived resolvins and pro-
tectins and the n-3 DPA-derived protectins. Multivariate ana-
lysis of lipid mediator proﬁles obtained from hippocampi of
sham mice and epileptogenic mice gave two distinct clusters
indicating that lipid mediator production is dysregulated
during epileptogenesis (Fig. 2C). Assessment of cumulative
levels for the distinct specialized pro-resolving mediator
families gave a downregulation of both DHA and n-3
DPA-derived resolvins and the arachidonic acid derived
lipoxins. We also observed an upregulation of DHA and n-
3 DPA derived protectins and eicosapentaenoic acid derived
resolvins (Fig. 3). Assessment of individual mediator concen-
tration gave statistically signiﬁcant decreases in RvD2n-3 DPA
and RvD5n-3 DPA as well as 5S,15S-diHETE, the lipoxin
pathway marker, and an upregulation of PD1n-3 DPA in tis-
sues from epileptogenic mice (Supplementary Table 2). These
results demonstrate that epileptogenesis leads to dysregula-
tion of specialized pro-resolving mediator production in the
brain.
PD1n-3 DPA regulates
neuroinflammation
Given that PD1n-3 DPA was markedly upregulated during epi-
leptogenesis, we next investigated whether this mediator was
involved in controlling neuroinﬂammation. Thus, we admin-
istered this mediator as its methylester form (PD1n-3 DPA-ME),
which is rapidly converted to the endogenous mediator in
biological tissues. Administration of PD1n-3 DPA-ME (20 or
200ng/ml) signiﬁcantly reduced in a dose-dependent manner
hippocampal Il1b and Tnfa mRNAs expression after status
epilepticus when compared to mice administered vehicle only
(Fig. 4). We also found that administration of this mediator
reduced the expression of inﬂammation-dampening mediator
IL-1Ra in brains from epileptogenic mice, likely because neu-
roinﬂammation was efﬁciently blunted by PD1n-3 DPA-ME. Of
note, PD1n-3 DPA-ME administration did not modify status
epilepticus onset, duration and severity (Supplementary Fig.
3). Together these results indicate that PD1n-3 DPA adminis-
tration controls the onset and propagation of neuroinﬂamma-
tion during epileptogenesis.
Effect of PD1n-3 DPA on early
pathological consequences of
status epilepticus
We next tested whether the protective mechanisms engaged
by PD1n-3 DPA also translated to improvements in weight
loss provoked by status epilepticus. Mice were administered
PD1n-3 DPA-ME or vehicle intracerebroventricularly for 4 days
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Figure 2 Dysregulated lipid mediator profiles in hippocampus of mice during epileptogenesis. Multiple reaction monitoring (A) for
identified mediators in murine brains. (B) MS/MS spectrum employed for the identification of PD1n-3 DPA. (C) Octagonal-partial least square
discriminant analysis of hippocampal lipid mediator profiles (top) 2D score plot; (bottom) 2D loading plot. Cumulative concentrations of bioactive
mediator families identified in hippocampi from mice following status epilepticus and sham mice. Lipid mediators were isolated, identified and
quantified using lipid mediator profiling in the hippocampus of mice 72 h post-status epilepticus (n = 16) and in sham mice (n = 8). See ‘Materials
and methods’ section for details. (C) P5 0.05 sham versus status epilepticus using Mann Whitney U-test.
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starting 1h after status epilepticus induction (Fig. 5A). Mice
exposed to status epilepticus and injected with vehicle (n = 7)
displayed a persistent loss of weight after status epilepticus
compared to sham mice (n = 9; Fig. 5B). In contrast, in mice
given PD1n-3 DPA-ME (n = 6), weight returned to those in
sham mice after 48h and this effect was sustained through
72h after status epilepticus (Fig. 5B). The baseline weight
measured the day before surgery was similar in the three
experimental groups (sham, 26.8  0.3g; saline,
24.4  0.4g; treatment, 25.9  0.6g).
To determine whether there PD1n-3 DPA also improved cog-
nitive function, we performed the novel object recognition test
(NORT) as a measure of non-spatial recognition memory.
During the recognition phase of the NORT, control mice
(n = 18) spent signiﬁcantly more time exploring the novel
object as compared to the familiar one (70% and 30% of
total exploration time, respectively), thus yielding a discrimin-
ation index of 0.37  0.03 (Fig. 5C). By contrast, mice injected
with saline and exposed to status epilepticus (n = 12) spent
equal time exploring previously presented and novel objects;
hence the discrimination index was 0.13  0.05 (Fig. 5C).
This deﬁcit was signiﬁcantly rescued in mice treated with
PD1n-3 DPA-ME (n = 11) since they spent more time exploring
the novel object thus yielding a discrimination index similar to
control mice (Fig. 5C). The deﬁcit in the NORT was not a
result of changes in spontaneous motor activity since the dis-
tance covered and the velocity of mice in the open ﬁeld were
not affected by status epilepticus or the treatment (sham,
3061  192cm; 5.1  0.3cm/s; saline, 3364  574cm;
5.3  0.6cm/s; PD1n-3 DPA-ME, 3890  613cm; 6.9 
1.2cm/s). As depicted in Fig. 5D, the three groups of mice
spent equal time (50%) exploring the two identical objects
during the familiarization phase, therefore excluding that the
changes in discrimination index were due to different objects’
exploration times.
At the end of the behavioural test, the mice were killed for
histopathological brain analysis. We did not detect signiﬁcant
differences in any of the cellular hallmarks measured in status
epilepticus-exposed mice treated with PD1n-3 DPA-ME versus
the corresponding vehicle-injected mice (Supplementary Fig.
4). In particular, there was an attenuation of the increased
number of ectopic doublecortin-positive cell in the hilus
(Supplementary Fig. 4A) as well as of astrogliosis and micro-
gliosis (Supplementary Fig. 4B) in status epilepticus-exposed
mice treated with by PD1n-3 DPA-ME versus vehicle, although
this effect did not reach statistical signiﬁcance. We measured a
signiﬁcant neuronal cell loss in the hippocampus (CA1, CA3)
and the kainic acid-injected amygdala as assessed by counting
Nissl-stained and Fluoro-Jade-positive neurons in status epi-
lepticus-exposed mice treated with vehicle (Supplementary
Figure 3 Epileptogenesis alters specialized pro-resolving mediator profiles in the hippocampus. The levels of DHA- and DPA-
derived protectins and resolvins, EPA-derived resolvins and AA-derived lipoxins were identified and quantified using LC-MS/MS-based liquid
mediator profiling (see ‘Materials and methods’ section for details) in the hippocampus of mice 72 h post-status epilepticus and in sham mice. Data
are presented as box-and-whisker plots depicting median, interquartile interval, minimum and maximum (n = 8 mice/group). RvDn-3 DPA
(P = 0.053); LX (P = 0.075); *P5 0.05; **P5 0.01 by Mann Whitney U-test.
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Fig. 4C and D). No signiﬁcant neuroprotection was measured
in PD1n-3 DPA-ME versus vehicle injected status epilepticus-
exposed mice (Supplementary Fig. 4C and D).
PD1n-3 DPA reduced ensuing epileptic
seizures
To test whether PD1n-3 DPA also regulates spontaneous seiz-
ures in mice, we administered the PD1n-3 DPA-ME (n = 9) or
saline (n = 12) for 4 days starting 1 h after status epilepticus
induction and cortical and hippocampal EEG activities
were measured continuously for 21 days to detect the
onset and frequency of spontaneous seizures (Fig. 6A and
B). Although the onset of spontaneous seizures was not
signiﬁcantly modiﬁed by PD1n-3 DPA-ME (Fig. 6C), the me-
diator signiﬁcantly reduced the cumulative number of daily
seizures after disease onset which is reﬂected by an average
50% reduction of daily seizure frequency (Fig. 6C and D).
The mean seizure duration was also signiﬁcantly reduced in
treated mice versus vehicle mice (Fig. 6B and C). As a
result, the total time spent in seizures was reduced by 3-
fold in mice treated with PD1n-3 DPA-ME (Fig. 6C). The
reduction in the average seizure duration persisted at Day
16 from epilepsy onset in PD1n-3 DPA-ME-treated mice
versus vehicle mice (vehicle, 41.4  3.8 s; PD1n-3 DPA-ME,
30.1  2.2, P5 0.05) despite the cumulative number of
seizures at this day was similar in the two experimental
groups (Fig. 6D).
The extent of neuronal cell loss in the hippocampus and
amygdala in the epileptic mice treated with PD1n-3 DPA-ME
during epileptogenesis was similar to vehicle-injected mice
(Supplementary Fig. 5), in accordance with the evidence at
96 h post-status epilepticus (Supplementary Fig. 4C). We
did not detect Fluoro-Jade-positive neurons in the epileptic
mice at the end of EEG recordings indicating that neuro-
degeneration was complete.
Supplementary results are included in the Supplementary
material.
Discussion
Neuroinﬂammation is ignited with a rapid onset by various
epileptogenic insults in both humans and animal models
and persists in brain areas where seizures originate and
spread (Gershen et al., 2015; Butler et al., 2016; Koepp
et al., 2017; Terrone et al., 2017; van Vliet et al., 2018).
We reasoned that the dynamics of this response might
point to inefﬁcient mechanisms of resolution in the diseased
brain tissue. Hence, lack of resolution may be a key factor
for the pathological consequences of neuroinﬂammation in
epilepsy (Vezzani et al., 2015).
Figure 4 PD1n-3 DPA regulates components of the inflammatory response in the hippocampus during epileptogenesis. (A)
Experimental design applied to status epilepticus-exposed mice to study the effect of PD1n-3 DPA-ME on proinflammatory and anti-inflammatory
mediators. One hour after status epilepticus onset, animals were randomized into a treatment arm injected intracerebroventricularly with either
20 ng/ml or 200 ng/ml PD1n-3 DPA-ME (n = 6–9) and a saline-injected group (n = 14). PD1n-3 DPA-ME or saline was injected for three consecutive
days starting 1 h after status epilepticus onset. Mice were sacrificed 72 h post-status epilepticus (2 h after the last injection of PD1n-3DPA-ME or
saline) for RT-qPCR analysis. Panels show mRNA levels of Il1b (IL-1b, B), Tnfa (TNF-, C) Il1rn (IL-1R, D) in the hippocampus of mice treated
with 20 ng/ml or 200 ng/ml dose of PD1n-3 DPA-ME (n = 6–9) or saline (n = 14) and in sham mice (n = 12). Reference genes were Mfsd5, Brap and
Bcl2l13. Data are presented on a log10 scale as box-and-whisker plots depicting median, interquartile interval, minimum and maximum
(n = number of mice).*P5 0.05; ** P5 0.01 by Kruskal-Wallis test with Dunn’s post hoc correction.
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We tested the novel hypothesis that the active pro-resol-
ving brain response mediated by fatty acid derivatives is
inefﬁcient in epilepsy, thereby contributing to persistent
neuroinﬂammation and the consequent seizure generation,
neuropathology and neurological deﬁcits. We focused our
investigations in the hippocampus, a key epileptogenic area,
in a well-established murine model of epileptogenesis where
combinations of anti-inﬂammatory drugs were proven to
block disease progression (Iori et al., 2017).
Similar to other epileptogenesis models (De Simoni et al.,
2000; Dhote et al., 2007; Maroso et al., 2011; Jiang et al.,
2013; Walker et al., 2017), we found an early and lasting
post-injury induction of the ictogenic cytokines IL-1b and
TNF- (Vezzani et al., 2011b; Balosso et al., 2013). Notably,
we also determined the lack of activation of LOX enzymes
and specialized pro-resolving mediator for hours to days
post-insult, indicating a delayed and transient activation
of the pro-resolving response as compared to neuroinﬂam-
mation. Lipid mediator proﬁling demonstrated differential
regulation in pro-resolving mediator concentrations during
epileptogenesis, that is characteristic of a failed resolution
response (Serhan, 2007, 2017), thus indicating that neu-
roinﬂammation contributing to epilepsy may arise from
an inability of the neuronal tissue to engage these host
protective pathways leading to tissue damage and neuronal
impairment.
Notably, PD1n-3 DPA was the most abundant lipid mediator
during epileptogenesis suggesting it might be a key player in
the tissue attempt to engage resolution pathways. Accordingly,
early post-injury administration of PD1n-3 DPA-ME signiﬁ-
cantly reduced neuroinﬂammation in our murine model, in
line with previous ﬁndings that PD1n-3 DPA and its precursor
n-3 DPA (Ferdinandusse et al., 2001) exert powerful anti-
inﬂammatory effects (Dalli et al., 2013). This effect was asso-
ciated with a drastic reduction in the number and duration
of spontaneous seizures after the onset of the disease. Since
PD1n-3 DPA-ME therapeutic effect occurred after treatment ter-
mination, we conclude that the drug mediates a genuine anti-
epileptogenic action rather than providing a mere symptomatic
control of seizures. Importantly, PD1n-3 DPA-ME improved
Figure 5 PD1n-3 DPA rescued weight loss and cognitive deficit during epileptogenesis. (A) Experimental design applied to status
epilepticus-exposed mice to study the effect of PD1n-3 DPA-ME on animal’s weight and recognition memory. One hour after status epilepticus
onset, mice were randomized into PD1n-3 DPA-ME (200 ng/ml) or saline group. Mice were injected intracerebroventricular for four consecutive
days starting 1 h after status epilepticus onset. (B) The weight of mice at baseline (the day before surgery) and at consecutive times after status
epilepticus. Mice were weighed daily (between 8:00 and 9:00 am) after administering saline (n = 7) or PD1n-3 DPA-ME (200 ng/ml; n = 6). Sham mice
(n = 9). Data are presented as box-and-whisker plots depicting median, interquartile interval, minimum and maximum (n = number of mice).
*P5 0.05; **P5 0.01 by Kruskal-Wallis test with Dunn’s post hoc correction. (C and D) The mice performance in the novel object recognition
test (NORT) starting 48 h post-status epilepticus. (C) The discrimination index [the ratio between the difference in time spent with the novel and
the familiar object (NF) and the sum of total exploration time (N + F)]. The test was performed 96 h after status epilepticus in mice injected with
saline (n = 12) or PD1n-3 DPA-ME (n = 11) and compared to sham mice (n = 18). (D) The exploration time (the ratio between the time spent
exploring the object and the total exploration time) during the familiarization phase when the two objects were identical. Data are presented as
box-and-whisker plots depicting median, interquartile interval, minimum and maximum (n = number of mice). *P5 0.05; **P5 0.01 versus sham
or saline by one-way ANOVA with Tukey’s post hoc test.
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Figure 6 PD1n-3 DPA reduced spontaneous seizures. (A) Experimental design in status epilepticus-exposed mice to study the effect of
PD1n-3 DPA-ME on spontaneous seizures. One hour after status epilepticus induction, animals were randomized into treatment (PD1n-3DPAME,
n = 9) and saline groups (n = 12). PD1n-3 DPA-ME (200 ng/ml) or saline was injected intracerebroventricularly for four consecutive days starting 1 h
after status epilepticus onset. EEG recording was done continuously from status epilepticus induction until the onset of the first two spontaneous
seizures (SRS) and for 16 days thereafter. At the end of EEG recording mice were sacrificed for brain histological analysis. Representative EEG
tracings depict baseline activity and spontaneous seizures recorded in the right hippocampus (Hippo) and in the left parietal cortex (CTX) of mice
treated with saline or PD1n-3 DPA-ME (B). Note the shorter duration of a typical EEG seizure in a drug-treated mouse versus saline-injected
mouse. (C) The onset of spontaneous seizures, the number of spontaneous seizures in each day of EEG recording, the average seizure duration
and the cumulative time spent in seizures in saline- (n = 12) versus drug-treated mice (n = 9). Data are presented as box-and-whisker plots
depicting median, interquartile interval, minimum and maximum (n = number of mice). (D) The cumulative number of seizures per day in each
experimental group during 16 days after epilepsy onset. *P5 0.05; **P5 0.01 versus saline injected mice by one-tailed t-test. Friedman’s two-way
non-parametric ANOVA was used to detect the treatment effect on number of seizures and duration and their interaction with days. Treatment
effect on number of seizures, P5 0.01 and interaction with days, P = 0.51; treatment effect on duration of seizures, P5 0.01 and interaction with
days, P = 0.82.
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animal’s weight recovery after status epilepticus and rescued
cognitive deﬁcit, a major neurological comorbidity in epilepsy
(Mazarati et al., 2017). Since neuroinﬂammation contributes
to both seizures and cognitive dysfunctions (Aronica et al.,
2017; Mazarati et al., 2017), the anti-inﬂammatory properties
of PD1n-3 DPA-ME are likely to chieﬂy mediate its therapeutic
effects. An unavoidable limitation of the murine model is the
short latency for the development of spontaneous seizures;
therefore, the treatment necessarily overlaps with the status
epilepticus. We have carefully quantiﬁed status epilepticus
onset, severity and duration and these parameters were not
changed by the early treatment with PD1n-3 DPA-ME.
Moreover, PD1n-3 DPA-ME did not reduce neuronal cell loss
in the hippocampus which is a direct consequence of status
epilepticus. Nevertheless, one cannot exclude there might be a
treatment effect on some acute modiﬁcations induced by status
epilepticus, which play a role in the therapeutic outcomes.
n-3 DPA is known to reduce the activation of microglia,
sphingomyelinase, caspase-3 and oxidative stress in aged
rats, and as a consequence to attenuate age-related deﬁcit
in spatial learning and long-term potentiation (Kelly et al.,
2011). Similarly, the DHA-derived NPD1 inhibited these
molecular processes in a model of Alzheimer’s disease
(Zhao et al., 2011) and also reduced hippocampal excit-
ability and seizures in rodents (Musto et al., 2011, 2015).
Since these molecular events are strictly associated with
neuroinﬂammation and play a role in seizure generation
(Balosso et al., 2008; Aronica et al., 2017; Pauletti et al.,
2017), they may be implicated in the antiepileptogenic ef-
fects of PD1n-3 DPA-ME.
Histopathological brain evaluation in PD1n-3 DPA-ME-treated
mice indicate a mild reduction in dentate hilus ectopic neuro-
genesis and in glial cells activation which are both implicated
in epileptogenesis (Scharfman and McCloskey, 2009), but no
neuroprotection was observed in forebrain. Differently, n-3
DPA exerted neuroprotective effects in the hippocampus of
aged rats after 56 days of diet supplementation (Kelly et al.,
2011), suggesting that a more prolonged post-injury treatment
with PD1n-3 DPA-ME is required to attain neuroprotective
effects.
Overall our data support the concept that resolution of
neuroinﬂammation and therapeutic effects on seizures and
cognition can be attained by enhancing brain endogenous
pro-resolving mediators. A potential clinical approach is to
increment the dietary intake of omega-3-polyunsaturated
fatty acids, which are known to be beneﬁcial for health
(Cash et al., 2014). Animal studies suggest that n-3 poly-
unsaturated fatty acids raise the seizure threshold but the
clinical studies have provided so far limited effects. This
might be because of insufﬁcient doses or too short periods
of administration (Taha et al., 2010). Long-term supple-
mentation may be required to produce high enough levels
of the active lipids in the brain. An advantage of this ap-
proach is the safety proﬁle of diet supplementation. Since
we observed induction of pro-resolving receptor expression
in the hippocampus of patients who had status epilepticus
or with drug-resistant seizures, treatments that enhance the
availability of endogenous receptor ligands might be war-
ranted. An alternative approach is to develop stable ana-
logues of specialized pro-resolving mediator, including
PD1n-3DPA, to overcome the limitation that they are meta-
bolically unstable. A notable example is the proven efﬁcacy
in a phase II clinical trial of a stable analogue of resolvin
E1 to treat dry eye symptoms. In this frame, our new evi-
dence of the anti-epileptogenic effect of PD1n-3 DPA-ME
highlights novel opportunity for drug discovery. However,
the brain penetration of these potential new drugs should
be improved for their therapeutic application in epilepsy,
unless intrathecal application is conceived. These drugs
might in principle be used as adjunctive therapy in patients
exposed to epileptogenic injuries or with ﬁrst presentation
of seizures to decrease the burden of the disease and ameli-
orate its clinical course.
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